Evidence mapPaperPMID 30006787Full record

ReviewJournal of artificial organs : the official journal of the Japanese Society for Artificial Organs2019

The biocompatibility and bioactivity of hemodialysis membranes: their impact in end-stage renal disease.

Michaela Kohlová, Célia Gomes Amorim, Alberto Araújo, Alice Santos-Silva, Petr Solich, Maria Conceição B S M Montenegro

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 73 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Dialysis and cognitive impairment.Nature reviews. Nephrology · 2025
    Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Michaela KohlováDepartment of Analytical Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czech Republic.
Célia Gomes AmorimDepartment of Chemical Sciences, Faculty of Pharmacy, LAQV-REQUIMTE, University of Porto, Rua de Jorge Viterbo Ferreira nº. 228, 450-313, Porto, Portugal.
Alberto AraújoDepartment of Chemical Sciences, Faculty of Pharmacy, LAQV-REQUIMTE, University of Porto, Rua de Jorge Viterbo Ferreira nº. 228, 450-313, Porto, Portugal.
Alice Santos-SilvaDepartment of Biological Sciences, Faculty of Pharmacy, UCIBIO-REQUIMTE, University of Porto, Rua de Jorge Viterbo Ferreira nº. 228, 450-313, Porto, Portugal. assilva@ff.up.pt.
Petr SolichDepartment of Analytical Chemistry, Faculty of Pharmacy in Hradec Králové, Charles University, Hradec Králové, Czech Republic.
Maria Conceição B S M MontenegroDepartment of Chemical Sciences, Faculty of Pharmacy, LAQV-REQUIMTE, University of Porto, Rua de Jorge Viterbo Ferreira nº. 228, 450-313, Porto, Portugal. mcbranco@ff.up.pt.
Charles University · CZRede de Química e Tecnologia · PTUniversidade do Porto · PT

Funding

Grantová Agentura, Univerzita Karlova 860216
6 · The paper itself

Abstract

End-stage renal disease is a growing health problem with increasing prevalence and high health care costs. Patients suffering from end-stage renal disease exhibit higher morbidity and mortality rates compared to the general population. These patients, who are treated using hemodialysis, typically suffer from anemia, inflammation, and oxidative stress. Inadequate dialyzer membrane biocompatibility exacerbates these negative side effects. Modifications of the composition of hemodialysis membranes have improved their biocompatibility and improve the patients' quality of life. Recently, the use of dialyzer membranes coated with bioactive compounds has also been proposed to further ameliorate dialysis-associated problems. Based on a survey of the current literature, application of bioactive membranes decreases the inflammation and oxidative stress of patients treated with hemodialysis.

Indexed as

Biocompatible MaterialsMembranes, ArtificialAntioxidantsCelluloseHumansInflammationKidney Failure, ChronicOxidative StressProteinase Inhibitory Proteins, SecretoryQuality of LifeRenal DialysisThioctic AcidVitamin EAntioxidantsBiocompatible MaterialsCelluloseMembranes, ArtificialProteinase Inhibitory Proteins, SecretoryThioctic AcidVitamin EBioactive membranesHemodialysis membranesInflammationKidney diseaseOxidative stress

Identifiers

PMID30006787
OpenAlexW2884137608

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.